Moderna, Inc. (NASDAQ:MRNA - Get Free Report)'s stock price rose 6.2% on Friday . The company traded as high as $40.99 and last traded at $40.63. Approximately 2,720,501 shares changed hands during trading, a decline of 43% from the average daily volume of 4,786,637 shares. The stock had previously closed at $38.25.
Analysts Set New Price Targets
A number of equities analysts have weighed in on MRNA shares. Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a report on Monday, November 18th. HSBC upgraded Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price on the stock in a report on Monday, November 18th. Needham & Company LLC reissued a "hold" rating on shares of Moderna in a research report on Friday, November 8th. Jefferies Financial Group reduced their target price on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a report on Tuesday, October 15th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Moderna from a "sell" rating to a "hold" rating and decreased their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Moderna presently has an average rating of "Hold" and a consensus target price of $84.00.
Get Our Latest Stock Analysis on Moderna
Moderna Stock Performance
The company's fifty day simple moving average is $54.96 and its two-hundred day simple moving average is $94.09. The company has a market capitalization of $15.82 billion, a price-to-earnings ratio of -7.06 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm earned ($1.39) earnings per share. The company's revenue for the quarter was up 3.8% compared to the same quarter last year. Equities research analysts predict that Moderna, Inc. will post -9.44 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company's stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 2,930 shares of company stock worth $217,170. 15.70% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Moderna
A number of hedge funds and other institutional investors have recently bought and sold shares of MRNA. Ashton Thomas Private Wealth LLC acquired a new position in Moderna during the 2nd quarter valued at approximately $26,000. Family Firm Inc. bought a new position in shares of Moderna during the second quarter worth about $33,000. Bank & Trust Co acquired a new stake in shares of Moderna in the 2nd quarter worth about $36,000. Hanseatic Management Services Inc. bought a new stake in Moderna in the 2nd quarter valued at about $48,000. Finally, Plato Investment Management Ltd boosted its stake in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock valued at $49,000 after purchasing an additional 288 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
See Also
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
